Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Duvelisib in CAR T-cell therapy for CLL

Edmund Waller • 1 Sep 2020
EBMT 2020
Chronic Lymphocytic Leukemia Leukemia Duvelisib

Edmund Waller, MD, PhD, FACP, Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, outlines the use and activity of duvelisib in CAR T-cell therapy for patients with chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Edmund Waller

1:12
Managing GvHD in patients undergoing SCT
Edmund Waller • 8 Sep 2023
1:46
Optimizing conditioning regimens in patients with AML undergoing alloSCT
Edmund Waller • 8 Sep 2023
2:09
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks
Edmund Waller • 8 Sep 2023
5:01
PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL
Edmund Waller • 23 Aug 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals